Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 3,596 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 3,596 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $79.55, for a total value of $286,061.80. Following the transaction, the director directly owned 776,477 shares in the company, valued at approximately $61,768,745.35. This represents a 0.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Liquidia Price Performance

Shares of LQDA opened at $86.82 on Wednesday. Liquidia Corporation has a 52 week low of $16.82 and a 52 week high of $91.10. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of 620.19 and a beta of 0.55. The stock has a 50 day moving average of $72.31 and a 200-day moving average of $50.98.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, analysts forecast that Liquidia Corporation will post 3.02 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Oppenheimer set a $75.00 price target on shares of Liquidia in a research report on Friday, June 5th. Bank of America reiterated a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Piper Sandler set a $129.00 target price on Liquidia in a research note on Friday. Finally, Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $86.18.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: LifeSci Capital maintained its Buy rating on Liquidia, supporting the bullish view of the company’s outlook. LifeSci Capital Sticks to Their Buy Rating for Liquidia
• Positive Sentiment: HC Wainwright expressed a positive view of Liquidia’s fiscal 2027 earnings prospects, suggesting analysts expect meaningful future growth. HC Wainwright Has Positive View of Liquidia FY2027 Earnings
• Positive Sentiment: Buckley Capital Advisors said Liquidia could have more than 50% upside, citing the upcoming YUTREPIA ruling and potential buyout interest. This reinforces the importance of regulatory and strategic catalysts for LQDA. Liquidia Has 50% Plus Upside on YUTREPIA Ruling and Buyout Potential
• Neutral Sentiment: Recent valuation coverage highlights a debate between YUTREPIA-driven growth and patent risk. Another analysis argues the stock still looks expensive as YUTREPIA expansion progresses, indicating that further appreciation depends on execution and successful intellectual-property outcomes. Liquidia Rallies as Fair Value Debate Turns on Growth and Patent Risk Liquidia Stock Still Looks Expensive
• Negative Sentiment: Director Stephen M. Bloch disclosed three sales totaling 178,596 shares for approximately $15.2 million between July 20 and July 23. Although he retained a substantial position, the sizable reduction could weigh on sentiment because it signals insider profit-taking after LQDA’s strong run. SEC Insider Transaction Filing

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB bought a new position in Liquidia in the 2nd quarter worth approximately $1,993,000. Fulcrum Equity Management bought a new stake in Liquidia during the 2nd quarter valued at $399,000. Fluent Financial LLC acquired a new position in Liquidia during the 2nd quarter worth $287,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia in the second quarter worth $1,395,000. Finally, Seven Fleet Capital Management LP increased its holdings in shares of Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after purchasing an additional 113,609 shares during the period. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).